At the news
? BULLISHIMPACT 6/10 COURT-RULING filed Aug 12, 2026 at 20:00 ET
The Fourth Circuit affirmed a district court's preliminary injunction barring Meritain Health, ProAct, and a group of alternative funding program operators (the 'Quartet') from importing, advertising, or facilitating the sale of Gilead's foreign-market HIV drug Biktarvy in the U.S. The court held that the imported drugs, though chemically identical and carrying authentic Gilead marks, are not 'genuine' under the Lanham Act due to materially different labeling and patient information (including Turkish-only text and omitted FDA-required warnings) and because they bypass Gilead's U.S. quality-control and recall systems. This unanimous published ruling removes a growing gray-market threat to Gilead's U.S. drug pricing and brand reputation, strengthening its intellectual property moat.
- The Fourth Circuit AFFIRMED the preliminary injunction against Meritain, ProAct, and the Quartet, finding Gilead likely to succeed on its Lanham Act trademark infringement claims.
- The imported Biktarvy, though chemically identical to the U.S. version, was deemed not 'genuine' due to material differences in labeling (Turkish instead of English, missing black box warnings, NDC numbers, FDA contact info) and because it shipped outside Gilead's U.S. quality-control system (no temperature monitoring, no pedigree records, outside recall protocols).
- The court found contributory infringement by Meritain (supplying patient data and processing claims for the import scheme despite a contrary written policy) and ProAct (programming system edits to redirect patients to the importers), applying a 'knowledge or reason to know' standard without requiring prior formal notice from Gilead.
- The ruling is a published, unanimous opinion by a three-judge panel, establishing binding Fourth Circuit precedent against gray-market importation of pharma products under the material-differences and quality-control doctrines.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access